How I Treat Multiple Myeloma?
Dr. Ehsan Malek
Assistant Professor Director, Multiple Myeloma Program Case Comprehensive Cancer Center Case Western Reserve University, USA
He received his MD from Shahid Beheshti School of Medicine, Iran, in 2004 before spending two years of post-Doc training in hematological translational research in University of Southern California, Keck School of Medicine, CA, US. He went on to receive Internal Medicine residency at University of Utah, UT, US and completed Hematology Oncology and Experimental Hematology fellowship at University of Cincinnati, OH, US, in 2014. He joined the malignant hematology section and stem cell program at Case Western Reserve University, Seidman Cancer Center, in Cleveland, OH, in 2015. He treats exclusively patients with plasma cell dyscrasia and his research interest mostly involves strategies to convert the permissive myeloma microenvironment, which is crucial in tumor promoting and bone resorption in these disorders. His group at Case Comprehensive Cancer Center (CCCC) is pioneering methods to manipulated TGF-beta signaling pathway for Multiple Myeloma which is being tested in multiple clinical trials currently. Also, He acts as Director of Multiple Myeloma Program at CCCC and leads a variety of immune therapies for Multiple Myeloma including CAR-T cells program. He is active member of Eastern Cooperative Oncology Group (ECOG), Multiple Myeloma committee guideline in National Comprehensive Cancer Network (NCCN), authored numerous manuscripts and serves as a reviewer for high impact hematology and cellular therapy journals.
Dr. Sahar Tavakoli
Assistant Professor, Hematologist Oncologist Oncology, Hematology and Cell Therapy Research Institute, Tehran University of Medical Sciences
Dr. Marjan Yaghmaie
Associate Professor, Head of Leading House for Iran-North America Academic Partnerships, Tehran University of Medical Sciences, Iran